← Leaderboards
Xiao-Jing Wang
University Of California At Davis
$25,575,023
Attributed
$34,182,877
Total exposure
21
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$44,255,962 · 20
VA$0 · 2
By mechanism
R01$18,830,458 · 8
P50$11,892,390 · 2
R44$5,925,801 · 4
T32$3,887,113 · 1
SB1$2,470,033 · 1
RC1$869,165 · 1
Top collaborators
- Antonio Jimeno14 shared
- Jing Hong Wang11 shared
- Christian Young9 shared
- Heather Callahan4 shared
- Brian Curtis Turner1 shared
Others in their field
Top investigators on “Mouse Model”
- Dennis R. Burton · Scripps Research Institute$280,661,242
- David Heimbrook · Leidos Biomedical Research, Inc.$84,491,283
- Kc Kent Lloyd · University Of California At Davis$74,285,556
- Alan F Horwitz · University Of Virginia Charlottesville$73,668,592
- Stanley B Prusiner · University Of California San Francisco$61,905,394
- Ed Lein · Allen Institute$59,425,748
Research focus
Mouse ModelTumorCellsSignal TransductionTransforming Growth FactorsBaseMalignant NeoplasmsMolecularTransforming Growth Factor BetaAffectMediatingHead And Neck CancerSamplingFutureSkinImmuneHead And Neck Squamous Cell CarcinomaDesignInflammationTherapeutic InterventionNeoplasm MetastasisT-LymphocyteTumor MicroenvironmentGenetically Engineered Mouse
Grant awards (119)
Colorado Head and Neck Cancer SPORE$1,950,049
P50 · FY2025 · CA
First-in-human clinical trial of proprietary oral gel to treat radiation-induced oral mucositis in cancer patients$1,233,852
R44 · FY2025 · CA
Treating recurrent HNSCC with radiation and dual TGF-Beta/PD-L1.$347,137
P50 · FY2025 · CA · contact PI
Colorado Head and Neck Cancer SPORE$89,760
P50 · FY2025 · CA
BLRD Research Career Scientist Award Application$0
IK6 · FY2025 · VA · contact PI
Mechanisms and Therapeutic Targets of SCC Metastasis$0
I01 · FY2025 · VA · contact PI
Colorado Head and Neck Cancer SPORE$1,813,896
P50 · FY2024 · CA
IND-enabling toxicology studies to reach IND approval for a proprietary biologic to treat oral mucositis in cancer patients$1,230,285
SB1 · FY2024 · DE
Treating recurrent HNSCC with radiation and dual TGF-Beta/PD-L1.$326,821
P50 · FY2024 · CA · contact PI
Treating recurrent HNSCC with radiation and dual TGF-Beta/PD-L1.$89,990
P50 · FY2024 · CA · contact PI
Colorado Head and Neck Cancer SPORE$89,990
P50 · FY2024 · CA
Treating recurrent HNSCC with radiation and dual TGF-Beta/PD-L1.$46,330
P50 · FY2024 · CA · contact PI
Colorado Head and Neck Cancer SPORE$46,330
P50 · FY2024 · CA
BLRD Research Career Scientist Award Application$0
IK6 · FY2024 · VA · contact PI
Mechanisms and Therapeutic Targets of SCC Metastasis$0
I01 · FY2024 · VA · contact PI
Colorado Head and Neck Cancer SPORE$1,817,388
P50 · FY2023 · CA
IND-enabling toxicology studies to reach IND approval for a proprietary biologic to treat oral mucositis in cancer patients$1,239,748
SB1 · FY2023 · DE
Mechanisms of Dual Inhibition of TGFbeta/PD-L1 in HNSCC$523,661
R01 · FY2023 · DE · contact PI
Colorado Head and Neck Cancer SPORE$475,000
P50 · FY2023 · CA
Treating recurrent HNSCC with radiation and dual TGF-Beta/PD-L1.$328,110
P50 · FY2023 · CA · contact PI
Mechanisms and Therapeutic Targets of SCC Metastasis$0
I01 · FY2023 · VA · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2023 · VA · contact PI
Colorado Head and Neck Cancer SPORE$1,822,219
P50 · FY2022 · CA
Elucidating Mechanism of Immune Evasion in Head and Neck Cancers$535,210
R01 · FY2022 · DE
Mechanisms of Dual Inhibition of TGFbeta/PD-L1 in HNSCC$450,789
R01 · FY2022 · DE · contact PI
Treating recurrent HNSCC with radiation and dual TGF-Beta/PD-L1.$328,109
P50 · FY2022 · CA · contact PI
Mechanisms of dual inhibition of TGFbeta/PD-L1 in HNSCC$82,061
R01 · FY2022 · DE · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2022 · VA · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2022 · VA · contact PI
Mechanisms and Therapeutic Targets of SCC Metastasis$0
I01 · FY2022 · VA · contact PI
Colorado Head and Neck Cancer SPORE$1,968,453
P50 · FY2021 · CA
Elucidating Mechanism of Immune Evasion in Head and Neck Cancers$561,945
R01 · FY2021 · DE
Mechanisms of dual inhibition of TGFbeta/PD-L1 in HNSCC$533,483
R01 · FY2021 · DE · contact PI
Training in Translational Research of Lung, Head and Neck Cancer$530,688
T32 · FY2021 · CA · contact PI
Proprietary drug to treat radiodermatitis$522,893
R44 · FY2021 · AR
Treating recurrent HNSCC with radiation and dual TGF-Beta/PD-L1.$352,808
P50 · FY2021 · CA · contact PI
Mechanisms and Therapeutic Targets of SCC Metastasis$0
I01 · FY2021 · VA · contact PI
Proprietary drug to treat radiodermatitis$1,157,986
R44 · FY2020 · AR
Elucidating Mechanism of Immune Evasion in Head and Neck Cancers$570,401
R01 · FY2020 · DE
Mechanisms of dual inhibition of TGFbeta/PD-L1 in HNSCC$533,483
R01 · FY2020 · DE · contact PI
Training in Translational Research of Lung, Head and Neck Cancer$437,608
T32 · FY2020 · CA · contact PI
Mechanisms of Breaking Indolence in Squamous Cell Carcinoma$0
I01 · FY2020 · VA · contact PI
Proprietary biologic treatment to heal skin wounds$715,021
R44 · FY2019 · DE
Elucidating Mechanism of Immune Evasion in Head and Neck Cancers$577,934
R01 · FY2019 · DE
Mechanisms of dual inhibition of TGFbeta/PD-L1 in HNSCC$533,483
R01 · FY2019 · DE · contact PI
Training in Translational Research of Lung, Head and Neck Cancer$420,921
T32 · FY2019 · CA · contact PI
Mechanisms of Breaking Indolence in Squamous Cell Carcinoma$0
I01 · FY2019 · VA · contact PI
Proprietary biologic treatment to heal skin wounds$796,049
R44 · FY2018 · DE
Topical proprietary biologic to treat oral mucositis$702,863
R44 · FY2018 · DE
Elucidating Mechanism of Immune Evasion in Head and Neck Cancers$585,209
R01 · FY2018 · DE
Training in Translational Research of Lung, Head and Neck Cancer$427,216
T32 · FY2018 · CA · contact PI
Mechanisms of Breaking Indolence in Squamous Cell Carcinoma$0
I01 · FY2018 · VA · contact PI
Topical proprietary biologic to treat oral mucositis$797,137
R44 · FY2017 · DE
Identifying oral cancer stem cell properties affected by the microenvironment$570,269
R01 · FY2017 · DE · contact PI
Training in Translational Research of Lung, Head and Neck Cancer$425,474
T32 · FY2017 · CA · contact PI
Training in Translational Research of Lung, Head and Neck Cancer$8,929
T32 · FY2017 · CA · contact PI
Mechanisms of Breaking Indolence in Squamous Cell Carcinoma$0
I01 · FY2017 · VA · contact PI
Identifying oral cancer stem cell properties affected by the microenvironment$501,568
R01 · FY2016 · DE · contact PI
Training in Translational Research of Lung, Head and Neck Cancer$439,355
T32 · FY2016 · CA · contact PI
Identifying oral cancer stem cell properties affected by the microenvironment$68,701
R01 · FY2016 · DE · contact PI
Training in Translational Research of Lung, Head and Neck Cancer$35,902
T32 · FY2016 · CA · contact PI
Identifying oral cancer stem cell properties affected by the microenvironment$501,568
R01 · FY2015 · DE · contact PI
Training in Translational Research of Lung, Head and Neck Cancer$433,044
T32 · FY2015 · CA · contact PI
Effects of Altering TGF Beta Signaling on Wound Healing$375,759
R01 · FY2015 · AR · contact PI
Training in Translational Research of Lung, Head and Neck Cancer$35,246
T32 · FY2015 · CA · contact PI
Identifying oral cancer stem cell properties affected by the microenvironment$500,090
R01 · FY2014 · DE · contact PI
Training in Translational Research of Lung, Head and Neck Cancer$442,776
T32 · FY2014 · CA · contact PI
Role of TGFbeta signaling in HNSCC progression$397,042
R01 · FY2014 · DE · contact PI
Effects of Altering TGF Beta Signaling on Wound Healing$368,245
R01 · FY2014 · AR · contact PI
Testing Smad7-based biologics for treating chronic wounds$194,672
R41 · FY2014 · AR · contact PI
Smad7 use in oral mucositis treatment$186,330
R43 · FY2014 · DE
Training in Translational Research of Lung, Head and Neck Cancer$34,966
T32 · FY2014 · CA · contact PI
Role of TGFbeta signaling in HNSCC progression$381,161
R01 · FY2013 · DE · contact PI
Effects of Altering TGF Beta Signaling on Wound Healing$356,971
R01 · FY2013 · AR · contact PI
Training in Translational Research of Lung, Head and Neck Cancer$214,988
T32 · FY2013 · CA · contact PI
Role of TGFbeta signaling in HNSCC progression$397,042
R01 · FY2012 · DE · contact PI
Effects of Altering TGF Beta Signaling on Wound Healing$375,759
R01 · FY2012 · AR · contact PI
Role of TGFbeta signaling in HNSCC progression$418,259
R01 · FY2011 · DE · contact PI
Effects of altering TGF beta signaling on wound healing$375,759
R01 · FY2011 · AR · contact PI
Role of Smads in the epidermis and skin carcinogenesis$275,868
R01 · FY2011 · CA · contact PI
Identification of normal and cancer stem cells and their niche in oral mucosa$434,060
RC1 · FY2010 · DE · contact PI
Role of TGFbeta signaling in HNSCC progression$394,715
R01 · FY2010 · DE · contact PI
Role of Smads in the epidermis and skin carcinogenesis$292,932
R01 · FY2010 · CA · contact PI
Identification of normal and cancer stem cells and their niche in oral mucosa$435,105
RC1 · FY2009 · DE · contact PI
Role of Smads in the epidermis and skin carcinogenesis$296,690
R01 · FY2009 · CA · contact PI
Role of TGF beta Signaling in skin carcinogenesis$248,234
R01 · FY2009 · CA · contact PI
Role of Smads in the epidermis and skin carcinogenesis$53,103
R01 · FY2009 · CA · contact PI
Role of Smads in the epidermis and skin carcinogenesis$315,985
R01 · FY2008 · CA · contact PI
Role of TGF beta signaling in Head Neck Squamous Cell Carcinoma progression$280,280
R01 · FY2008 · DE · contact PI
Role of TGF beta Signaling in skin carcinogenesis$192,500
R01 · FY2008 · CA · contact PI
Role of TGF beta signaling in Head Neck Squamous Cell Carcinoma progression$66,072
R01 · FY2008 · DE · contact PI
Role of TGF beta Signaling in skin carcinogenesis$26,912
R01 · FY2008 · CA · contact PI
Role of TGF beta signaling in Head Neck Squamous Cell Carcinoma progression$298,677
R01 · FY2007 · DE · contact PI
Role of Smads in the epidermis and skin carcinogenesis$297,737
R01 · FY2007 · CA · contact PI
Role of TGF beta Signaling in skin carcinogenesis$248,100
R01 · FY2007 · CA · contact PI
Effects of altering TGF beta signaling on wound healing$226,994
R01 · FY2007 · GM · contact PI
Role of TGF beta signaling in HNSCC progression$307,598
R01 · FY2006 · DE · contact PI
Role of TGF beta Signaling in skin carcinogenesis$254,541
R01 · FY2006 · CA · contact PI
Effects of altering TGF beta signaling on wound healing$233,774
R01 · FY2006 · GM · contact PI
Role of TGF beta signaling in HNSCC progression$315,000
R01 · FY2005 · DE
Role of TGF beta Signaling in skin carcinogenesis$280,511
R01 · FY2005 · CA
Effects of altering TGF beta signaling on wound healing$239,400
R01 · FY2005 · GM
Role of TGF beta signaling in HNSCC progression$315,000
R01 · FY2004 · DE
Effects of altering TGF beta signaling on wound healing$239,400
R01 · FY2004 · GM
ROLE OF SMADS IN THE EPIDERMIS AND SKIN CARCINOGENESIS$238,827
R01 · FY2004 · CA
ROLE OF SMADS IN THE EPIDERMIS AND SKIN CARCINOGENESIS$206,700
R01 · FY2003 · CA
TGF BETA SIGNALING AND SKIN CARCINOGENESIS$155,132
R01 · FY2003 · CA
TGF BETA SIGNALING AND SKIN CARCINOGENESIS$77,515
R01 · FY2003 · CA
TGF BETA SIGNALING AND SKIN CARCINOGENESIS$225,422
R01 · FY2002 · CA
ROLE OF SMADS IN THE EPIDERMIS AND SKIN CARCINOGENESIS$188,548
R01 · FY2002 · CA
ROLE OF SMADS IN THE EPIDERMIS AND SKIN CARCINOGENESIS$77,918
R01 · FY2002 · CA
Smad in skin /appendage development$0
P01 · FY2002 · AR
ROLE OF SMADS IN THE EPIDERMIS AND SKIN CARCINOGENESIS$235,463
R01 · FY2001 · CA
TGF BETA SIGNALING AND SKIN CARCINOGENESIS$195,664
R01 · FY2001 · CA
ROLE OF SMADS IN THE EPIDERMIS AND SKIN CARCINOGENESIS$22,575
R01 · FY2001 · CA
TGF BETA SIGNALING AND SKIN CARCINOGENESIS$7,525
R01 · FY2001 · CA
Smad in skin /appendage development$0
P01 · FY2001 · AR
ROLE OF SMADS IN THE EPIDERMIS AND SKIN CARCINOGENESIS$235,463
R01 · FY2000 · CA
TGF BETA SIGNALING AND SKIN CARCINOGENESIS$187,831
R01 · FY2000 · CA